Free Trial
NASDAQ:PMCB

PharmaCyte Biotech (PMCB) Stock Price, News & Analysis

PharmaCyte Biotech logo
$1.32 -0.06 (-4.35%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$1.27 -0.05 (-3.41%)
As of 03/28/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PharmaCyte Biotech Stock (NASDAQ:PMCB)

Key Stats

Today's Range
$1.29
$1.46
50-Day Range
$1.32
$1.81
52-Week Range
$1.29
$2.55
Volume
11,380 shs
Average Volume
21,782 shs
Market Capitalization
$9.06 million
P/E Ratio
2.49
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Remove Ads

PharmaCyte Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

PMCB MarketRank™: 

PharmaCyte Biotech scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for PharmaCyte Biotech.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PharmaCyte Biotech is 2.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.58.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PharmaCyte Biotech is 2.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.60.

  • Price to Book Value per Share Ratio

    PharmaCyte Biotech has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.44% of the float of PharmaCyte Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    PharmaCyte Biotech has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PharmaCyte Biotech has recently increased by 82.31%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    PharmaCyte Biotech does not currently pay a dividend.

  • Dividend Growth

    PharmaCyte Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.44% of the float of PharmaCyte Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    PharmaCyte Biotech has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PharmaCyte Biotech has recently increased by 82.31%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    PharmaCyte Biotech has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for PharmaCyte Biotech this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added PharmaCyte Biotech to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PharmaCyte Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.20% of the stock of PharmaCyte Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 34.24% of the stock of PharmaCyte Biotech is held by institutions.

  • Read more about PharmaCyte Biotech's insider trading history.
Receive PMCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter.

PMCB Stock News Headlines

Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
PharmaCyte Biotech Inc PMCB
PharmaCyte Biotech Invests In Femasys - Quick Facts
See More Headlines

PMCB Stock Analysis - Frequently Asked Questions

PharmaCyte Biotech's stock was trading at $1.57 at the beginning of the year. Since then, PMCB shares have decreased by 15.9% and is now trading at $1.32.
View the best growth stocks for 2025 here
.

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) released its quarterly earnings data on Monday, March, 17th. The company reported ($0.10) EPS for the quarter.

Top institutional shareholders of PharmaCyte Biotech include Citadel Advisors LLC and Concourse Financial Group Securities Inc..

Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PharmaCyte Biotech investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), ASML (ASML), General Electric (GE), Oracle (ORCL) and Nokia Oyj (NOK).

Company Calendar

Last Earnings
3/17/2025
Today
3/31/2025
Fiscal Year End
4/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PMCB
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
2.49
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.27 per share
Price / Book
0.40

Miscellaneous

Free Float
6,896,000
Market Cap
$9.06 million
Optionable
Optionable
Beta
-0.25
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:PMCB) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners